Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 3,729 | 262 | 300 | 300 | 383 |
| Gross Profit | 3,729 | 262 | 300 | 300 | 383 |
| Operating Expenses | 146,363 | 120,686 | 88,515 | 72,617 | 52,433 |
| Operating Income | -142,634 | -120,424 | -88,215 | -72,317 | -52,050 |
| Interest Expense | 44 | 457 | 1,082 | 1,190 | 10,672 |
| Other Income | 3,110 | 294 | 27 | 31 | -195 |
| Pre-tax Income | -139,568 | -120,587 | -89,270 | -73,476 | -62,917 |
| Income Tax | 3,000 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -142,568 | -120,587 | -89,270 | -73,476 | -62,917 |
| Net Income | $-142,568 | $-120,587 | $-89,270 | $-73,476 | $-62,917 |
| EPS Basic Total Ops | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 |
| EPS Basic Continuous Ops | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 |
| EPS Diluted Total Ops | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 |
| EPS Diluted Continuous Ops | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 |
| EPS Diluted Before Non-Recurring Items | -3.94 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-142,011 | $-118,546 | $-85,558 | $-69,721 | $-48,546 |